Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 21, Number 10—October 2015

Human Infection with Ehrlichia muris–like Pathogen, United States, 2007–20131

Diep K. Hoang Johnson2, Elizabeth Schiffman2, Jeffrey P. Davis, David Neitzel, Lynne M. Sloan, William L. Nicholson, Thomas R. Fritsche, Christopher R. Steward, Julie A. Ray, Tracy K. Miller, Michelle A. Feist, Timothy S. Uphoff, Joni J. Franson, Amy L. Livermore, Alecia K. Deedon, Elitza S. Theel, and Bobbi PrittComments to Author 
Author affiliations: Wisconsin Department of Health Services, Madison, Wisconsin, USA (D.K. Hoang Johnson, J.P. Davis, C.R. Steward, A.K. Deedon); Minnesota Department of Health, St. Paul, Minnesota, USA (E.K. Schiffman, D.F. Neitzel, J.A. Ray); Mayo Clinic, Rochester, Minnesota, USA (L.M. Sloan, E.S. Theel, B.S. Pritt); Centers for Disease Control and Prevention, Atlanta, Georgia, USA (W.L. Nicholson); Marshfield Clinic, Marshfield, Wisconsin, USA (T.R. Fritsche, T.S. Uphoff); North Dakota Department of Health, Bismarck, North Dakota, USA (T.K. Miller, M.A. Feist); Mayo Clinic Health System, Eau Claire, Wisconsin, USA (J.J. Franson); Mayo Medical Laboratories, Andover, Massachusetts, USA (A.L. Livermore).

Main Article

Table 1

Number of real-time PCR tests to detect Ehrlichia species/Anaplasma phagocytophilum performed by year and detection of the EML pathogen among samples from residents of Minnesota and Wisconsin, 2004–2013*

Testing 2004† 2005 2006 2007 2008 2009 2010 2011 2012 2013
No tests performed 275 520 779 1,224 1,909 2,198 4,365 7,349 7,723 13,639
No. (%) EML positive
0 (0)
0 (0)
0 (0)
2 (0.2)
1 (0.1)
5 (0.2)
9 (0.2)
23 (0.3)
7 (0.1)
17 (0.1)
*Numbers of patients with EML-positive samples do not include 5 EML-positive samples submitted from patients outside MN and WI (2009–2013) who likely acquired infection in MN and WI. EML, Ehrlichia muris–like; †First year that PCR assay was used for clinical testing.

Main Article

1Preliminary data from this study were presented at the American Society for Clinical Laboratory Science–Minnesota meeting, March 8, 2012, St. Cloud, Minnesota, USA; the Interscience Conference of Antimicrobial Pathogens and Chemotherapy, September 9–12, 2012, San Francisco, California, USA; the Emerging Infections in Clinical Practice and Public Health Continuing Medical Education Conference, November 16, 2012, Minneapolis, Minnesota, USA; the Interscience Conference of Antimicrobial Pathogens and Chemotherapy, September 10–13, 2013, Washington, DC, USA; the Entomological Society of America annual meeting, November 10–13, 2013, Austin, Texas, USA; the American Society of Tropical Medicine and Hygiene annual meeting, November 13–17, 2013, Washington, DC, USA; the European Congress of Clinical Microbiology and Infectious Diseases, May 10–13, 2014, Barcelona, Spain; and the International Conference on Diseases in Nature Communicable to Man, August 10–12, 2014, Vancouver, British Columbia, Canada.

2These authors contributed equally to this article.

Page created: September 22, 2015
Page updated: September 22, 2015
Page reviewed: September 22, 2015
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.